HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Matti Kivikko Selected Research

Simendan (Levosimendan)

3/2020Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use.
1/2020Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use.
12/2019A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus.
12/2018Repetitive levosimendan treatment in the management of advanced heart failure.
1/2018Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications.
9/2017Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy.
11/2016Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper.
9/2016The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion.
7/2016Effect of baseline characteristics on mortality in the SURVIVE trial on the effect of levosimendan vs dobutamine in acute heart failure: Sub-analysis of the Finnish patients.
12/2015Oral Levosimendan Increases Cerebral Blood Flow Velocities in Patients with a History of Stroke or Transient Ischemic Attack: A Pilot Safety Study.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Matti Kivikko Research Topics

Disease

25Heart Failure
03/2020 - 01/2002
3Pulmonary Hypertension
03/2020 - 01/2009
2Cardiogenic Shock
03/2020 - 01/2020
2Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
03/2020 - 01/2020
2Takotsubo Cardiomyopathy
03/2020 - 01/2020
2Hypotension (Low Blood Pressure)
09/2016 - 04/2010
2Stroke (Strokes)
12/2015 - 03/2015
1Heart Diseases (Heart Disease)
03/2020
1Low Cardiac Output
11/2016
1Acute Coronary Syndrome
09/2016
1Myocardial Infarction
07/2016
1Heart Arrest (Cardiac Arrest)
07/2016
1Oliguria
07/2016
1Ventricular Premature Complexes (Premature Ventricular Contraction)
12/2015
1Ischemic Stroke
12/2015
1Transient Ischemic Attack
12/2015
1Brain Ischemia (Cerebral Ischemia)
12/2015
1Sepsis (Septicemia)
12/2013
1Cholestasis
03/2013
1Myocardial Ischemia (Ischemic Heart Diseases)
12/2012
1Critical Illness (Critically Ill)
05/2011
1Fatigue
04/2010
1Alcoholic Liver Cirrhosis (Alcoholic Cirrhosis)
04/2008
1Headache (Headaches)
05/2007
1Hypokalemia
05/2007
1Atrial Fibrillation
05/2007
1Renal Insufficiency (Renal Failure)
01/2007
1Chronic Kidney Failure (Chronic Renal Failure)
01/2007

Drug/Important Bio-Agent (IBA)

25Simendan (Levosimendan)IBA
03/2020 - 01/2002
5CalciumIBA
12/2019 - 01/2002
4DobutamineFDA LinkGeneric
12/2019 - 05/2007
3Vasodilator Agents (Vasodilators)IBA
12/2019 - 04/2008
3N- (4- (4- methyl- 6- oxo- 1,4,5,6- tetrahydropyridazin- 3- yl)phenyl)acetamide (OR 1896)IBA
04/2008 - 04/2004
2Potassium Channels (Potassium Channel)IBA
01/2018 - 12/2013
2CreatinineIBA
07/2016 - 01/2007
1Type 3 Cyclic Nucleotide PhosphodiesterasesIBA
12/2019
1Norepinephrine (Noradrenaline)FDA LinkGeneric
12/2019
1Dopamine (Intropin)FDA LinkGeneric
12/2019
1Epinephrine (Adrenaline)FDA LinkGeneric
12/2019
1Adrenergic beta-Agonists (beta-Adrenergic Agonists)IBA
12/2019
1CatecholaminesIBA
12/2019
1DiureticsIBA
12/2019
1Milrinone (Primacor)FDA LinkGeneric
12/2019
1Brain Natriuretic Peptide (Natrecor)FDA Link
09/2017
1LiraglutideFDA Link
09/2017
1Vasoconstrictor AgentsIBA
09/2016
1Alanine (L-Alanine)FDA Link
07/2016
1Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
07/2016
1TransferasesIBA
07/2016
1Glucose (Dextrose)FDA LinkGeneric
07/2016
1Valsartan (Vals)FDA Link
03/2015
1Transaminases (Aminotransferases)IBA
03/2013
1Biological ProductsIBA
03/2013
1Biomarkers (Surrogate Marker)IBA
12/2012
1pro-brain natriuretic peptide (1-76)IBA
12/2008
1Pharmaceutical PreparationsIBA
01/2007

Therapy/Procedure

5Therapeutics
12/2018 - 05/2011
2Critical Care (Surgical Intensive Care)
03/2020 - 01/2020
1Subcutaneous Injections
09/2017
1Intravenous Infusions
04/2010